Cargando…
Erratum to: Serum T3 Level and Duration of Minimum Maintenance Dose Therapy Predict Relapse in Methimazole-Treated Graves Disease
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7888528/ https://www.ncbi.nlm.nih.gov/pubmed/33644624 http://dx.doi.org/10.1210/jendso/bvab015 |
Ejemplares similares
-
Serum T3 Level and Duration of Minimum Maintenance Dose Therapy Predict Relapse in Methimazole-Treated Graves Disease
por: Thewjitcharoen, Yotsapon, et al.
Publicado: (2020) -
Efficacy of low-dose methimazole in control of multiple relapses of Graves’ hyperthyroidism: a case report
por: Azizi, Fereidoun, et al.
Publicado: (2021) -
Methimazole-Induced Pleural Effusion in the Setting of Graves' Disease
por: Khine, Le Yu, et al.
Publicado: (2019) -
Efficacy and adverse events related to the initial dose of methimazole in children and adolescents with Graves’ disease
por: Lee, Hyun Gyung, et al.
Publicado: (2021) -
Lower serum uric acid level predicts mortality in dialysis patients: Erratum
Publicado: (2021)